Extrawell Pharmaceutical Holdings Limited (HKG:0858)
Hong Kong · Delayed Price · Currency is HKD 0.0810
-0.0010 (-1.22%)
At close: Feb 13, 2026
HKG:0858 Income Statement
Financials in millions HKD. Fiscal year is April - March.
Millions HKD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 52.65 | 55.43 | 59.1 | 72.58 | 73.93 | 78.8 | |
Revenue Growth (YoY) | -11.41% | -6.21% | -18.57% | -1.82% | -6.19% | 1.57% |
Cost of Revenue | 30.32 | 33.56 | 30.32 | 41.43 | 36.37 | 36.24 |
Gross Profit | 22.33 | 21.87 | 28.78 | 31.14 | 37.56 | 42.57 |
Selling, General & Admin | 32.56 | 30.9 | 35.25 | 42.42 | 50.5 | 53.43 |
Operating Expenses | 32.56 | 30.9 | 35.25 | 42.42 | 50.5 | 53.43 |
Operating Income | -10.24 | -9.03 | -6.47 | -11.28 | -12.94 | -10.87 |
Interest Expense | -24.02 | -22.11 | -18.8 | -15.64 | -13.23 | -11.24 |
Interest & Investment Income | 4.29 | 4.98 | 5.67 | 2.99 | 1.08 | 5.17 |
Earnings From Equity Investments | -3.34 | -2.31 | -2.28 | -3.85 | -3.65 | -2.88 |
Other Non Operating Income (Expenses) | -4.05 | -1.84 | -4.74 | -0.27 | -7.76 | 3.82 |
EBT Excluding Unusual Items | -37.35 | -30.31 | -26.61 | -28.05 | -36.5 | -16 |
Gain (Loss) on Sale of Investments | -299.06 | 254.9 | -132.93 | 158.66 | 168.64 | -104.7 |
Gain (Loss) on Sale of Assets | 0.01 | 0.01 | - | - | -0.06 | - |
Other Unusual Items | 0.12 | 0.12 | 0.12 | 0.28 | 0.25 | 1.04 |
Pretax Income | -336.29 | 224.72 | -159.42 | 130.9 | 132.33 | -119.66 |
Income Tax Expense | 0.97 | 1.17 | 2.13 | 1.13 | 1.24 | - |
Earnings From Continuing Operations | -337.25 | 223.55 | -161.56 | 129.77 | 131.09 | -119.66 |
Earnings From Discontinued Operations | -0.08 | -0.11 | -0.09 | - | - | - |
Net Income to Company | -337.33 | 223.45 | -161.64 | 129.77 | 131.09 | -119.66 |
Minority Interest in Earnings | -0.69 | -0.8 | -1.31 | -0.51 | -0.5 | -1.44 |
Net Income | -338.02 | 222.64 | -162.95 | 129.27 | 130.59 | -121.1 |
Net Income to Common | -338.02 | 222.64 | -162.95 | 129.27 | 130.59 | -121.1 |
Net Income Growth | - | - | - | -1.01% | - | - |
Shares Outstanding (Basic) | 2,399 | 2,390 | 2,390 | 2,390 | 2,390 | 2,390 |
Shares Outstanding (Diluted) | 2,399 | 3,290 | 2,390 | 3,290 | 3,290 | 2,390 |
Shares Change (YoY) | -8.25% | 37.66% | -27.36% | - | 37.66% | -27.36% |
EPS (Basic) | -0.14 | 0.09 | -0.07 | 0.05 | 0.05 | -0.05 |
EPS (Diluted) | -0.14 | 0.07 | -0.07 | 0.04 | 0.04 | -0.05 |
EPS Growth | - | - | - | 0.78% | - | - |
Free Cash Flow | -8.47 | -7.44 | -4.89 | -5.44 | -11.39 | -1.57 |
Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
Gross Margin | 42.41% | 39.46% | 48.70% | 42.91% | 50.80% | 54.02% |
Operating Margin | -19.44% | -16.29% | -10.95% | -15.54% | -17.51% | -13.79% |
Profit Margin | -642.07% | 401.67% | -275.73% | 178.11% | 176.65% | -153.67% |
Free Cash Flow Margin | -16.10% | -13.42% | -8.28% | -7.49% | -15.41% | -2.00% |
EBITDA | -3.74 | -2.47 | 0.82 | -4.63 | -6.4 | -4.9 |
EBITDA Margin | -7.10% | -4.46% | 1.38% | -6.38% | -8.66% | -6.22% |
D&A For EBITDA | 6.5 | 6.56 | 7.29 | 6.65 | 6.54 | 5.97 |
EBIT | -10.24 | -9.03 | -6.47 | -11.28 | -12.94 | -10.87 |
EBIT Margin | -19.44% | -16.29% | -10.95% | -15.54% | -17.51% | -13.79% |
Effective Tax Rate | - | 0.52% | - | 0.86% | 0.94% | - |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.